Melanoma Matters14 Loka 2024

Ep 44: Treatment Beyond Progression

Summary

More stories about medical emergencies! In this conversation, James Larkin and Sapna Patel discuss the complexities of tumor dynamics in patients treated with pembrolizumab beyond disease progression. They share personal anecdotes about medical emergencies on flights, which lead into a deeper exploration of treatment strategies and clinical trial methodologies. The discussion emphasizes the importance of understanding patient responses to treatment, the limitations of traditional assessment tools like RESIST, and the need for careful consideration in trial designs to avoid premature conclusions about new therapies.

Keywords

tumor dynamics, pembrolizumab, treatment beyond progression, medical emergencies, clinical trials, cancer treatment, immunotherapy, patient care, melanoma, PD-1

Takeaways

Treatment beyond progression can yield clinical benefits.

RECIST criteria may not accurately reflect patient responses to immunotherapy.

Understanding disease trajectory is crucial in treatment decisions.

Clinical trials must be designed to account for patient variability.

The importance of patient monitoring during treatment is emphasized.

AI could revolutionize tumor assessment in clinical practice.

Caution is advised when interpreting early trial results.

Stepwise progression in trial design can save resources.

Titles

Innovations in Tumor Assessment

Cautionary Tales in Cancer Research

Chapters

00:00 Medical Emergencies on Flights

10:46 Treatment Beyond Progression in Cancer

16:49 Clinical Trials and Patient Outcomes

26:47 Cautionary Tales in Cancer Treatment

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(88)

Ep 84: Merlin CP-GEP and Castle i31-SLNB tests

In this episode, the chin dimple is front and center. James explains the wizarding home of Tintagel in Cornwall to Sapna, situated on a lovely promontory. This episode explores the latest evidence on ...

24 Heinä 0s

Ep 83: Guest Megan Othus and Time of Day Administration

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...

24 Kesä 40min

Ep 82: Best of ASCO: 2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...

13 Kesä 1h 4min

Live from ASCO 2026: a preview

James & Sapna sent a brief message from ASCO 2026 about what they are looking forward to hearing at the meeting.OptimUM-02ADAMKN-942Neoadjuvant pilot studies... and more

1 Kesä 6min

Ep 81: IGNYTE trial (RP1 + nivo)

SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into cli...

13 Helmi 32min

Ep 80: 2025 Holiday Special

SummaryHappy Holidays and Festive Season Everyone! In this episode of Melanoma Matters, hosts Sapna Patel and James reflect on their "cultural" experiences over the past year, discussing movies, music...

30 Joulu 202535min

Ep 79: coBRIM, COMBI-d 5-year follow-up

SummaryIn this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-...

29 Joulu 202536min